Rafferty Asset Management’s Lexeo Therapeutics LXEO Stock Holding History
Bought
Maintained
Sold
Other funds holding LXEO
Rafferty Asset Management's LXEO Position: Q3 2026 in Review
Rafferty Asset Management increased its Lexeo Therapeutics (LXEO) stake by 1.7% in Q3 2026, buying an estimated $5.15K and bringing the position to 68,672 shares worth $232K. The position accounts for ﹤0.01% of the portfolio, ranked #1059.
Rafferty Asset Management first reported a position in LXEO in Q4 2025 and has held it in 4 quarters since. The position peaked at $1.01M in Q4 2025. 153 funds tracked by Wall St. Rank hold LXEO as of Q3 2026.
- Rafferty Asset Management held 68,672 shares of Lexeo Therapeutics worth $232K as of Q3 2026.
- Rafferty Asset Management bought 1,137 Lexeo Therapeutics shares in Q3 2026, an estimated $5.15K.
- Lexeo Therapeutics made up ﹤0.01% of Rafferty Asset Management's portfolio in Q3 2026, its #1059 holding.
- Rafferty Asset Management first reported a position in Lexeo Therapeutics in Q4 2025 and has held it in 4 quarters since.
- Rafferty Asset Management's Lexeo Therapeutics position peaked at $1.01M in Q4 2025.
- 153 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q3 2026.
Based on Rafferty Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.